Aviptadil
As of the edition of 20 October 2026, Aviptadil is a protein: marketed; acts on ADRA1A, ADRA1B and ADRA1D and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Brand name
- Corpin
- Approvals on record
- 7 in 7 regions
- Holder of the most recent approval
- Evolan Pharma Ab
- Registered trials
- 9, 3 stopped early
- Disease areas
- Lungs and airways; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 5 | 3 | 0 | 2 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Centurion Pharma | Lead sponsor of trials | 2021 to now |